SHANGHAI, March 30, 2017 /360WiseNews/ — WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec Affiliate, today announced that it had received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm.
Asia-Pacific Bioprocessing Excellence Awards aims to recognize outstanding leaders and trend-setters of today, and inspire innovators of tomorrow. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and best practices in manufacturing, WuXi Biologics has been recognized for its outstanding performance that facilitating biomanufacturing excellence at enhanced speed, reduced cost and superior quality.
As an open-access biologics technology platform, WuXi Biologics opened its state-of-the-art biologics manufacturing facilities at Wuxi city in 2012, which is the first in China that met cGMP standards of the United States, the European Union, and China. In 2015, WuXi began construction of world’s largest mammalian cell culture manufacturing facility using disposable bioreactors with a planned manufacturing capacity of 30000L, and completed construction of Asia’s largest perfusion biologics manufacturing facility using disposable bioreactors in 2016, offering end-to-end solution to our worldwide customers and partners. Keep Reading